-
Health Technology Assessment, Reimbursement, and Funding Landscape Challenges for Oncology Companion Diagnostics in Europe and Canada
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization and Costs Among Various Disease States in Adults With Hepatitis Delta Virus in Inpatient and Outpatient Settings in the United States
Sep 9, 2025, 16:22 PM -
Clinically Informed, Cost-Sensitive Machine Learning for Predicting Hospital-Acquired Pressure Injuries: A Practical Approach Using Routinely Collected Data
Sep 9, 2025, 16:22 PM -
The Value of Medical Spending in China, 1991-2019
Sep 9, 2025, 16:22 PM -
A Real-World Retrospective Cohort Study Characterizing Healthcare Resource Utilization and Costs Among Patients With MMN in the United States
Sep 9, 2025, 16:22 PM -
Broader Economic Effects of Investment in Cancer Control in Commonwealth Countries
Sep 9, 2025, 16:22 PM -
Relationship Between Cost-Effectiveness Threshold and Drug Reimbursement in Spain, Italy, and France
Sep 9, 2025, 16:22 PM -
Exploring the Healthcare Resource Utilization (HCRU) Associated With Chorea in Patients With Huntington's Disease (HD): A Systematic Literature Review (SLR)
Sep 9, 2025, 16:22 PM -
A Comparison of Treatment Costs for CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative HR+/HER2-: Early Breast Cancer (EBC) in Sweden
Sep 9, 2025, 16:22 PM -
Bridging the Regulatory-Payer Evidence Gap: A Case Study With Six Minute Walk Distance and Mortality
Sep 9, 2025, 16:22 PM -
Psychometric Validation Of The North Star Assessment For Limb-Girdle Type Muscular Dystrophies (NSAD) In Limb-Girdle Muscular Dystrophy Sarcoglycanopathies (LGMD 2C/2D/2E) Using Baseline JOURNEY Data...
Sep 9, 2025, 16:22 PM -
Single-Agent vs. Multi-Agent RAG for Health Economic Model Replication: A Comparative Evaluation
Sep 9, 2025, 16:22 PM -
Predicting SMC Appraisal Outcomes Using Machine Learning: A Model to Support Early Market Access Strategy
Sep 9, 2025, 16:22 PM -
Utilization of Best-Value Medicines for Teriparatide in the Irish Healthcare Setting
Sep 9, 2025, 16:22 PM -
A Cost-Effectiveness Analysis of First-Line Therapies for Microsatellite-Instability-High (MSI-H) or Mismatch-Repair-Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (mCRC) in France
Sep 9, 2025, 16:22 PM -
Cost-per-Remission of Vedolizumab vs. Risankizumab for the Treatment of Moderate-to-Severely Active Crohn’s Disease in Italy, France, and Canada
Sep 9, 2025, 16:22 PM -
Quality and Impact of Real-World Data in Chronic Disease Research: Insights From Retrospective Studies Using the Hospital Episode Statistics (HES) Database
Sep 9, 2025, 16:22 PM -
From Complex Statistics to Clinically Meaningful Insights: Interpreting Results in Meta-Analyses of Continuous Outcomes
Sep 9, 2025, 16:22 PM -
Balancing Fit and Accuracy: Evaluating Survival Model Projections With Immature Data in Health Technology Assessments
Sep 9, 2025, 16:22 PM -
From Evidence to Enforcement? Implications of the 2025 SVR Report for Pharmaceutical Pricing and Orphan Drug Policy in Germany
Sep 9, 2025, 16:22 PM
